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Abstract
Patient safety is an aim for clinical applications and is a fundamental principle 
of healthcare and quality management. The main global health organizations have 
incorporated patient safety in their review of work practices. The data provided by 
the medical laboratories have a direct impact on patient safety and a fault in any 
of processes such as strategic, operational and support, could affect it. To provide 
appreciate and reliable data to the physicians, it is important to emphasize the need 
to design risk management plan in the laboratory. Failure Mode and Effect Analysis 
(FMEA) is an efficient technique for error detection and reduction. Technical 
Committee of the International Organization for Standardization (ISO) licensed a 
technical specification for medical laboratories suggesting FMEA as a method for 
prospective risk analysis of high-risk processes. FMEA model helps to identify qual-
ity failures, their effects and risks with their reduction/elimination, which depends 
on severity, probability and detection. Applying FMEA in clinical approaches can 
lead to a significant reduction of the risk priority number (RPN).
Keywords: Patient Safety, Medical Laboratory, Risks, Failure Modes, Processes
1. Introduction
All medical cares, including clinical laboratories, carries an intrinsic risk of errors 
that can result in harm, disability, and even death so today their activities have seen 
a significant increase in monitoring [1]. In the past, laboratory processes performed 
in clinical laboratories focused only on results, while today, they focus on issues 
related to reliability, safety and effectiveness. It is very important in health world, 
being aware of the error rate attributable to health system that has great impact on 
patients [2]. Currently, some strategies are proposed to analyze and to see how you 
can decline the rate of preventable errors. In order to guarantee reliable results and 
improved data consistency, while operating with reduced funding, laboratories 
need to acquire a new culture of management, more tools and specific training [3]. 
Research management founded on a quality approach is emerging as an essential tool 
to ensure valuable, vigorous and dependable consequences, within a framework of 
the best practice. Risk management has been disseminated in clinical laboratories 
only for the last years, although it has been applied in healthcare since the 80s. That 
was partly due to constant inspections during the cycle of laboratory examination, 
rework, removal of any defects and adjustment after the identification of possible 
causes of flaws or errors. One of the instruments used in risk management is the 
analysis of failure modes and effects analysis (FMEA). The FMEA model has been 
applied in various medical fields, including clinical laboratory activities to improve 
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patient safety before serious harm to their health. By reducing/eliminating errors, 
the FMEA model helps to prevent and control failures and their risks in clinical 
approaches [4].
2. Failure mode and effect analysis: background and description
Failure mode and effect analysis (FMEA) which was first developed in the 1940s 
is a systematic technique for identifying all possible errors in a system or process. 
Adoption of this analysis by National Aeronautics and Space Administration 
(NASA) in relation with aerospace missions in mid-1960s made its practical applica-
tion possible. Since then, this analysis has been widely used in diverse industries 
such as oil and gas, food and automotive and electronics systems. In recent years 
FMEA has been also successfully applied in the health system as an effective tool for 
improving patient safety and performance in hospitals. Today, The FMEA is emerg-
ing as a tool for assessing the risk of clinical trial processes and clinical analytical 
methods. However, there are still too few reports about this last use and even fewer 
data are available on the application of the methodology in clinical laboratories 
[5–8]. The risk assessment in this technique involves identification of potential 
errors, determining the severity (S), occurrence (O) and effects of each error and 
reviewing the control actions implemented to prevent or detect (D) errors [9] 
(Figure 1). In the traditional FMEA, to measure these criteria, a numeric scale of 1 
to 10 is used (Table 1). Thus, each failure mode is been ranked by a scale called Risk 
Priority Number (RPN) characterized by multiplying the numbers of three criteria 
(S, O, D) together. Therefore, the higher the RPN value, the more important the 
error is and its correction has more priority. So, RPN is so beneficial to identify high 
risk failures modes requiring priority functions [10, 11].
Prevention, reducing or excluding of errors and their risk is an essential 
requirement in clinical analytical tests which is been established by the laboratory 
according to RPN limit. The laboratory decided the assessing scale of frequency, the 
severity and errors detection which is being different for each test. There are three 
main categories of errors [12, 13]:
I. Critical errors – Mainly through request for analysis, if not identified and  
corrected early, have serious consequences for the patient’s health
II. Major errors – resulting from the inappropriate application of the sampling  
method
III. Minor errors – considered so, because of the low probability of occurrence, 
the high probability of detection or low/absent severity. These errors are 
taken into account only with the purpose to review the method and the 
technical instruction
Classification of potential errors occurred in the clinical laboratory processes 
which are subjected to the samples shown in Table 2 (The following items only 
examples of errors and do and does not include all clinical laboratory failure 
modes) [14, 15].
In clinical laboratories all errors should be controlled by quality indicators. 
To monitor and assess periodically laboratories’ involvement in patients’ care the 
implementation of quality indicators is necessary. ISO/TS 22367 supports the 
non-conformities, errors and incidents identifying in the clinical laboratory, with 
an emphasis on the pre-analytical and post-analytical processes. These processes are 
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Severity scale (scale 1 [least severe] to 10 [most severe] for each effect)
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Detection scale for occurrence (scale 1 [always detected] to 10 [never detected] for each occurrence)
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Failure Modes and Effects Analysis Scale for Severity, Probability, and Detection. (I): Severity score (S): 1 to 
10 scales from least to most severe (II) Probability score (P): 1 to 10 scales from least to most probable  
(III) Detectability score (D): 1 to 10 scales from most to least detectable.
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the most critical and the most difficult ones to control due to involving of various 
specialists, sections and centers [16]. Clinical laboratory process map is shown in 
Figure 2. The processes map together with the risk map can give us an overview of 
the failures distribution in each of the processes [3].
Like any analytical method, FMEA should be thoroughly understood prior to 
being introduced in laboratory practice. There are five stages in its implementation 
which will be explained in more detail in the methodology [17–19].
FMEA assessment resulted in actions to address the root causes, determining the 
following situations:
• risk reduction through the development of a preventive action plan to promote 
process improvement;
• immediate removal of the risk source when the pieces of equipment were 
increased;
• change in the probability of certain risks when the selection process for new 
employees was initiated;
• sharing the risk with other staff members when the clinical emergency staff 
was involved in the potential problem.
FMEA contributed to quality planning, allowing the evaluation of intercon-
nected activities designed to generate products and assisting in the identification of 
controls.
2.1 FMEA in clinical laboratory activities and patient’ safety
Errors in the laboratory activities can lead to consequences in patients’ safety. 
That’s why these errors should be identified, controlled and reduced. Effective 
patient treatment can be improved by prevention and detection of the errors at the 
time of occurrence which in turn ensures the patient’ safety. Currently, the tendency 
to move from the traditional technical adopted like internal quality control (IQC) 
and external quality assessment (EQA) to risk management is seen in all quality 
systems of clinical laboratories. It is conclusive the need for risk management in 
clinical laboratories and monitoring them within the quality plan, a fact that would 
lead to an increase on patient safety. Studies have revealed that FMEA is useful for 
detecting errors and improving patients’ safety and it can yield benefits, for failures 
management and general process improvement, within a laboratory system where 
Pre-analytical Analytical Post-analytical
Incorrect identification of 
the patient
Procedural non-conformity Incorrect result
Mislabeling of samples Errors of equipment or 
reagents
Result sent to a different patient
Incorrect tube for sampling 
or incorrect storage
Discrepancies in the results of 
the internal control
Introducing incorrectly the results in 
the system
Improper or prolonged 
transport conditions
Delay in analyzing the 
samples
Lack of information about the limits 
concerning the results’ interpretation
Table 2. 
Potential errors occurred in the clinical laboratory processes.
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time and team input is limited, and within a process that was considered to have few 
obstacles [1–4]. Former study showed that FMEA can effectively reduce errors in 
clinical chemistry laboratories [20].
Woodhouse et al. showed applying FMEA for identified processes in a hemo-
therapy service, can reduced the possibility of error occurrence and increased the 
probability of detection [21]. Momenizadeh et al. concluded that implementing 
FMEA can significantly reduce laboratory errors [22]. Molavi-Taleghani et al. argued 
that FMEA method is very effective in identifying the possible failure of treatment 
procedures, determining the cause of each failure mode, and proposing improve-
ment strategies [23]. Applying the FMEA risk assessment tool to laboratory processes 
can increase effectiveness, efficiency and reproducibility of the results [24]. Risk 
management in the clinical laboratory by FMEA can decrease the possibility of errors 
occurrence and ensures the accuracy of results and patient’s safety. Risk management 
guidelines recommended that the clinical laboratories must have a proactive and indi-
vidualized role in reducing the potential errors by developing an appreciate Quality 
Figure 2. 
Processes map of clinical laboratory.
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Control Plan (QCP). The laboratories must create their own analytic process to 
identify the weakness of each testing stage. As errors and their risks were identified, 
the laboratories select the appropriate control processes to detect and to prevent the 
occurrence of errors. All errors and control processes are mentioned in the QCP [25].
2.2 FMEA benefits and barriers
The Benefits of implementing FMEA approach in clinical laboratories include 
enhancing patients’ safety, improving quality of tests, reducing the chances of 
repeating the same failure, cost and time and encouragement for teamwork and 
effective communication between functions – collaboration [26]. In comparison 
with other quality improvement tools FMEA can be fairly compared, its risk can be 
assessed, and a score can be assigned.
FMEA also has some barriers such as limits of human error analysis (traditional 
FMEA uses potential equipment/system failures) and missing interactions between 
faults and external influences. The reproducibility and generalizability of FMEA in 
clinical laboratory approaches are factors of concern but since this method is based 
on hypothetical possibilities uncertainty is still likely to remain [27]. Previous study 
showed that using FMEA is more time-consuming than other hazard analysis that 
identifies failure modes but the improvement potentially obtainable by FMEA in 
a clinical laboratory is high, and this fact should suggest further experiences in 
this field. Despite the barriers, FMEA represents an appreciate, comprehensive, 
and organized approach to known potential patient safety failure modes in clinical 
laboratory [28–30]. processes. According to the risk-based thinking introduced by 
new ISO 9001:2015 standard, FMEA is an appropriate approach errors analysis of 
operational processes under an ISO-certified Quality Management System [31].
3. Methodology
Analytical methodology of FMEA is very effective in maintaining patient safety. 
Laboratory staffs trained in FMEA methodology can greatly reduce time require-
ments and guarantee that all activities involved are coordinated increasing the 
accuracy of laboratory results [17–19].
The FMEA process including 5 steps as follow:
1. Selecting a process for study;
2. Assembling a multidisciplinary team;
3. Collecting and organizing data about the selected process;
4. Analysis of hazards;
5. Developing and implementing appropriate actions and measuring the 
outcomes;
3.1 Selecting a process for study
The intricacy of laboratory processes increases the probability of undesirable 
errors. The more steps in the process and the greater their dependency, the greater 
the chance of error. In this step the laboratory identifies the critical processes based 
on the severity of possible harmful errors and the potentially dangerous impact on 
patient safety [17–19].
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3.2 Assembling a multidisciplinary team
Gathering specialists with different levels and types of training, with specific 
knowledge and experience of the selected process. A team head can lead team 
members through the process, and can help ensure that team members complete 
each step and record the results of FMEA [17–19].
3.3 Collecting and organizing data about the selected process
In this step the assembled team creates an accurate diagram of potential failure 
modes of each listed activity using focus laboratory staff activities and reaching a 
common conclusion and recording it on FMEA form (Table 3) [17–19].
3.4 Analysis of hazards
This step including identifying failure modes in each step, determining the 
potential effect of each failure mode, ranking the severity of failure mode effects, 
ranking the probability and detectability of each failure mode and identifying the 
critical failure modes [17–19].
3.5  Developing and implementing appropriate actions and measuring the 
outcomes
Identifying the root causes of critical failures is an important step in develop-
ing an appropriate action plan. Traditional root cause analysis methods are used to 
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determine the underlying cause of each critical failure so that appropriate actions 
can be taken. Once the root causes of critical failures have been identified, the team’s 
aim is to eliminate the risk of failures, reduce the likelihood of failure or mitigate the 
effects of failure should it affect the patient [17–19].
4. Discussion
Clinical laboratories processes tend to errors due to human interactions and 
instrumental mistakes. Therefore, it is essential to design plans to make errors 
preventable. In the clinical laboratory, most errors are in the pre-analytical phase. 
The criteria for risk assessment designing plans for preventive errors were defined in 
the laboratory. There is no standard for developing and implementing of these plans 
in the laboratory, impediment the comparison between pairs and application of best 
practices. Some of the staff laboratory features, namely the ability to think analyti-
cal and simultaneously to establish standard policies and strict adherence to proto-
cols, helped in the prevention of the potential errors. These plans for risk assessment 
can help reduce the occurrence of adverse errors. FMEA may become the common 
standard for measurement and comparison, particularly in clinical laboratories. In 
fact, the total testing process is intricate, consisting of numerous steps that are not 
always taken under the control of laboratory experts. Current evidence on the strati-
fication of errors in clinical laboratory strongly supports the introduction of FMEA 
for further reducing error rates, particularly in the extra-analytical steps. While the 
first aim of FMEA is to promote an approach to ensuring the safety of laboratory 
processes, total cost reduction should be simultaneously achieved when considering 
the entire process of patient safety [13–16].
Mascia et al. shows that the FMEA risk management approach as applied to 
a scientific processes is in line with the current needs of management models to 
raise effectiveness and efficiency, to enhance reproducibility, and to facilitate a 
rapid industrialization of obtained results [24]. In order to achieve reliable results 
in long run of clinical laboratory approaches Momenizadeh et al. suggested that 
the managers of the laboratories of Markazi province (Iran) should focus on the 
implementation of the FMEA [22]. Sudhakar et al. reported that FMEA is a ben-
eficial technique to decrease quality failures in clinical biochemistry laboratories. 
As compared to other prospective risk analysis approaches, FMEA prevent and 
solve high risk failure modes in clinical laboratories [32]. Previous study stated 
the efficiency of FMEA risk assessment to detect and to adjust the quality control 
procedures in order to improve the analytical performance of clinical chemistry 
laboratories [33].
In all clinical laboratories a risk assessment approach is required according to ISO 
17025:2017 standard dedicated to laboratories measurement, in order to improve 
uncertainty and thus the reliability and reproducibility of results. Performing 
FMEA to processes in the laboratory facilitates evaluation high-risk processes tend 
to failure before an error happen. By assuming and compensating for less-than-per-
fect human performance, FMEA promotes error prevention through identification 
of valuable and consensually accepted quality indicators in all steps of the testing 
process [34].
5. Conclusion
Clinical laboratories are inseparable part of health care system as they help 
in appropriate diagnosis of patient’s health. Their working process is a complex 
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procedure which may associate with certain errors. Improvement of the patients’ 
safety by reducing the errors and their risks in clinical laboratories is a great chal-
lenge. High-quality clinical laboratories ensure that they perform standard tasks, 
monitor, and improve their performance, creating a culture of transparency, 
defining responsibilities, and optimizing patients’ safety. FMEA is very effective 
and successful technique in preventing errors, improving quality and safety of 
tests, identifying potential errors, and prioritizing clinical laboratory improvement 
strategies. FMEA had a multidisciplinary approach and its complex configuration 
processes involvement facilitated the management of errors. As compared to other 
prospective risk analysis methods, FMEA analysis provides a good solution for 
high risk failure modes in clinical laboratories. Therefore, FMEA is a suitable and 
efficient tool to identify most clinical laboratory errors to improving the quality of 
laboratory processes and ensuring the accuracy of obtained results and maintaining 
patient health and safety. The overall purpose of this paper is to encourage clinical 
laboratories to assess and monitor their own. In addition, it should be possible to 
identify and monitor error rates to improve upon the process on the basis of objec-
tive and desirable quality specifications.
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